• Skyline Isolations

Regulation of Nausea and Vomiting by Cannabinoids and the Endocannabinoid System

Updated: Nov 8, 2018

ABSTRACT

Seizures are difficult to control in the Dravet syndrome, a rare genetic form of epileptic encephalopathy primarily due to loss-of-function mutations in the SCN1A gene. Interest in cannabidiol for the treatment of epilepsy was generated by media reports of efficacy in children with the Dravet syndrome. Four small trials of cannabidiol had yielded mixed results. A series of in vitro and in vivo preclinical models of seizure showed that cannabidiol had activity against convulsive seizures. Subsequently, the safety and effectiveness of a standardized oral solution of cannabidiol was tested in an open-label trial involving 214 children and young adults with drug-resistant epilepsy. We conducted a randomized, double-blind, placebo-controlled trial of cannabidiol to treat drug-resistant epilepsy in the Dravet syndrome.

CLICK TO READ FULL STUDY

KEY WORDS: #CBD #Seizures #DravetSyndrome #Epilepsy #Epileptic

SOURCE: New England Journal of Medicine

AUTHORS: Orrin Devinsky, M.D.,J. Helen Cross, Ph.D., F.R.C.P.C.H., Linda Laux, M.D., Eric Marsh, M.D., Ian Miller, M.D., Rima Nabbout, M.D., Ingrid E. Scheffer, M.B., B.S., Ph.D., Elizabeth A. Thiele, M.D., Ph.D., Stephen Wright, M.D.

ABOUT

CONTACT US

SHOP

  • Skyline Isolations Instagram
  • Skyline Isolations Facebook
  • Skyline Pinterest
  • Skyline Isolations LinkedIn
  • Skyline Isolations Twitter

© 2017 by Skyline Isolations LLC

DISCLAIMER: SKYLINE DOES NOT MAKE ANY CLAIMS, BUT DISCUSSES PUBLICLY AVAILABLE ANECDOTAL EVIDENCE, RESOURCES AND BOTH EDUCATIONAL AND MEDICAL JOURNALS.

Products may have o.1% of THC content or less.